Squarepoint
ABOS icon

Squarepoint’s Acumen Pharmaceuticals ABOS Stock Holding History

Squarepoint’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140K Buy
52,351
+37,336
+249% +$92.2K ﹤0.01% 4139
2026
Q1 		$35.4K Buy
+15,015
New +$38.3K ﹤0.01% 4159
2025
Q2 		– Sell
-11,189
Closed -$12.3K – 4420
2025
Q1 		$12.3K Sell
11,189
-626
-5% -$894 ﹤0.01% 4457
2024
Q4 		$20.3K Buy
+11,815
New +$28.4K ﹤0.01% 4935
2024
Q2 		– Sell
-113,232
Closed -$459K – 3983
2024
Q1 		$459K Buy
113,232
+60,403
+114% +$228K ﹤0.01% 3105
2023
Q4 		$203K Buy
+52,829
New +$157K ﹤0.01% 3589
2023
Q3 		– Sell
-10,445
Closed -$50.2K – 3723
2023
Q2 		$50.2K Sell
10,445
-8,898
-46% -$42.6K ﹤0.01% 3439
2023
Q1 		$78.5K Buy
+19,343
New +$101K ﹤0.01% 3015
2022
Q1 		– Sell
-18,818
Closed -$127K – 2741
2021
Q4 		$127K Buy
+18,818
New +$207K ﹤0.01% 2860

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Squarepoint's ABOS Position: Q2 2026 in Review

Squarepoint increased its Acumen Pharmaceuticals (ABOS) stake by 249% in Q2 2026, buying an estimated $92.2K and bringing the position to 52,351 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #4139.

Squarepoint first reported a position in ABOS in Q4 2021 and has held it in 9 quarters since. The position peaked at $459K in Q1 2024. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Squarepoint held 52,351 shares of Acumen Pharmaceuticals worth $140K as of Q2 2026.
  • Squarepoint bought 37,336 Acumen Pharmaceuticals shares in Q2 2026, an estimated $92.2K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4139 holding.
  • Squarepoint first reported a position in Acumen Pharmaceuticals in Q4 2021 and has held it in 9 quarters since.
  • Squarepoint's Acumen Pharmaceuticals position peaked at $459K in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.